$CGON
CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.
Healthcare
Sector
Biotechnology
Industry
Arthur Kuan
CEO
113
Employees
$70.40
Current Price
$4.41B
Market Cap
Insider Activity Statistics
Aggregated buying and selling activity by time period
| Period | Type | Insiders | Transactions | Value | Shares | Buy/Sell Ratio |
|---|---|---|---|---|---|---|
| 1 week | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 2 weeks | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 1 month | Buys | 0 | 0 | - | - | All Sells |
| Sells | 1 | 1 | $1,138,956.00 | 15,600 | ||
| 2 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 1 | 3 | $1,263,670.00 | 17,564 | ||
| 3 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 1 | 3 | $1,263,670.00 | 17,564 | ||
See activity going back 12 months โ create a free account | ||||||
Insider Transactions
Recent purchases and sales by company insiders
| Date | Insider | Type | Shares | Price | Value | Actions |
|---|---|---|---|---|---|---|
| Apr 17, 2026 | Mulay James Director | Sale | 15,600 | $73.01 | $1,138,956.00 | View Details |
| Mar 16, 2026 | Mulay James Director | Sale | 654 | $63.50 | $41,529.00 | View Details |
| Mar 16, 2026 | Mulay James Director | Sale | 1,310 | $63.50 | $83,185.00 | View Details |
22 more transactions available โ create a free account to see 12 months of history | ||||||
Upcoming Earnings
Scheduled earnings reports
No upcoming earnings scheduled
Past Earnings
Historical earnings results
No past earnings data available